Objective, reproducible, and trustworthy data in clinical trials with imaging endpoints

Dr. Anthony Tolcher, medical oncologist and CEO of NEXT Oncology, spoke to us about objectivity as one of the biggest challenges in clinical trials and how a software solution for tumor assessment can improve the quality and reproducibility of data, all while saving time.

Moreover, such software solutions are a key aspect for the approval of novel drugs based on small sample size – like for example targeted or tissue agnostic medicine, as a significant advance for precision therapies. Dr. Tolcher describes how mint Lesion™ assists in generating trustworthy data, “so that [one] can ensure that the drugs that are getting approved really do work.”

Click here or on the image above to watch the full video on YouTube.

Structured Reporting Clinical Trials Standardized Reading Procedures Therapy Response Assessment Video

Related Resources

Related Resources

mint Analytics: Real-time data visualization and analysis in clinical trials with imaging endpoints

We talked to PD Dr. Wolfgang G. Kunz, Head of Oncological Imaging and of the Oncological Study Center at the Ludwig Maximilians University Hospital…

University Hospital Cologne: Study provides guidance values of iodine concentration for body CT examinations

Using data from a large cohort of individuals without radiological tumor burden, researchers from University Hospital Cologne have conducted a study…

Private Practice KölnTriangle: Catapulted into a New Orbit of Reporting

With mint Lesion™, “complex information is condensed so that it is easier to understand. We believe that this way, we can make the complex central…